<DOC>
	<DOCNO>NCT01773785</DOCNO>
	<brief_summary>The primary purpose study determine effectiveness SPI-1620 combination docetaxel patient advance biliary cancer .</brief_summary>
	<brief_title>Phase II Study SPI-1620 Combination With Docetaxel Second-Line Treat Biliary Cancer</brief_title>
	<detailed_description />
	<mesh_term>Biliary Tract Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Histologically confirm biliary tract gallbladder cancer relapse refractory one prior gemcitabinebased chemotherapy regimen advance biliary cancer Evaluable disease ECOG PS ≤ 2 Adequate bone marrow , liver renal function Treatment one prior chemotherapy regimen Known , uncontrolled CNS metastasis Baseline peripheral neuropathy ≥ grade 2 . Significant circulatory disorder past 6 month Concomitant use phosphodiesterase inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>